Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Sensitivity, Specificity, and Predicted Value

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?

Clinical pharmacology and therapeutics·2026

Same author

PK and PK/PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With Microdosing.

CPT: pharmacometrics & systems pharmacology·2026

Same author

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026

Same author

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Expert opinion on drug metabolism & toxicology·2026

Same journal

Access Challenges in Allogeneic Hematopoietic Cell Transplant: Identifying At-Risk US States by Exploring Social Vulnerability, Physician Density, and Unmet Need.

JCO oncology practice·2026

Same journal

Getting It Right the First Time: Improving Antibiotic Stewardship in Febrile Oncology Patients Presenting to the Pediatric Emergency Department.

JCO oncology practice·2026

Same journal

Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non-Small Cell Lung Cancer.

JCO oncology practice·2026

Same journal

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

JCO oncology practice·2026

Same journal

Timing Is Not Everything: Reassessing Chrono-Immunotherapy in Clinical Practice.

JCO oncology practice·2026

Same journal

Survival Outcomes in Breast Cancer Patients With Use of Vaginal Estrogen Therapy: A SEER Analysis.

JCO oncology practice·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Large-Scale DPD Testing Should Be More Than an Option

Marie-Christine Etienne-Grimaldi¹, Bernard Royer¹, Manon Launay¹

¹Marie-Christine Etienne-Grimaldi, PhD, PharmD, Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France; Bernard Royer, PhD, PharmD, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon and Univ. Franche-Comté, INSERM, EFS BFC, UMR1098, Besançon, France; Manon Launay, PhD, PharmD, Institut Curie, Service de Pharmacologie, Saint-Cloud, France; Antonin Schmitt, PhD, PharmD, Pharmacy Department, Centre Georges-François Leclerc, Dijon and INSERM U1231, University of Burgundy Franche-Comté, Dijon, France; Fabienne Thomas, PhD, PharmD, Oncopole Claudius Regaud, Institut Universitaire du Cancer and CRCT, University of Toulouse, Inserm, Toulouse, France; and Joseph Ciccolini, PhD, PharmD, COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 and University Hospital of Marseille, Marseille, France.

JCO Oncology Practice

|December 3, 2024

Summary

No abstract available in PubMed .

More Related Videos

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System

Published on: May 22, 2020

Related Experiment Videos

Last Updated: Jun 6, 2025

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System

Measuring Sub-23 Nanometer Real Driving Particle Number Emissions Using the Portable DownToTen Sampling System

Published on: May 22, 2020